With data analytics and more specific billing codes, the government has improved its ability to identify medically unnecessary genetic testing and other fraudulent activity.
The preliminary approval is the penultimate step to bringing to a close a class action lawsuit accusing Celera of making false and misleading statements about its finances.
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Investors are suing China Medical Technologies alleging the firm engaged in actions that artificially inflated its stock in violation of US securities law.
Signal filed its suit against Med BioGene earlier this month alleging a breach of agreement, violation of a confidentiality agreement, and misuse of proprietary information, among other charges.
In a document filed with the SEC, Sequenom said that Elizabeth Dragon has pled guilty to charges of making false statements about the company's prenatal test for Down syndrome and will be sentenced on Aug. 30.
